Premium
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs
Author(s) -
KÜNG K.,
RIOND J.L.,
WANNER M.
Publication year - 1993
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1993.tb00212.x
Subject(s) - enrofloxacin , pharmacokinetics , ciprofloxacin , metabolite , active metabolite , pharmacology , oral administration , medicine , oral dose , chemistry , antibiotics , biochemistry
Rung, K., Riond, J.‐L. & Wanner, M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J. vet Four dogs were given 5 mg/kg body weight enrofloxacin intravenously (i.v.) and orally (p.o.) in a cross‐over study. Plasma concentrations of the active ingredient enrofloxacin and its main metabolite ciprofloxacin were determined by a reversed phase liquid chromatographic method. Pharmacokinetic parameters of both substances were calculated by use of statistical moments and were compared to those of enrofloxacin described in the veterinary literature. Mean enrofloxacin t ½λZ was 2.4 h, mean Cl s was 27.1 ml/min‐kg, and mean V ss was 7.0 1/kg. After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (C max = 0.2 ng/ml, max = 2.2 h after intravenous administration; C max = 0.2 (ig/ml, t max = 3.6 h after oral administration). A considerable part of the antimicrobial activity is due to ciprofloxacin, the main metabolite of enrofloxacin.